The world’s most comprehensive and practical reference source about drugs and medicines

Unrivalled in its field, Martindale provides practical, evidence-based, global guidance, allowing you to quickly understand the characteristics of drugs and other pharmaceutical substances and their clinical uses.

SubscribeContent Updates
Features and Benefits icon

Global source of information: International, multi-lingual coverage, including synonyms, drug and chemical identifiers, chemical formulae, structures and pharmacopeial standards

Features and Benefits icon

Breadth of content: Expertly curated data on over 248,000 medicines provides an unparalleled, consolidated database of preparations

Features and Benefits icon

Range of drugs: Provides concise and accurate information on herbals, diagnostic agents, radiopharmaceuticals, pharmaceutical excipients, toxins and poisons

Features and Benefits icon

Reviewed and updated every 3 months by expert teams

7,500 +

drugs

54,000

references

40

regions and countries covered

6 +

languages

Publication Updates

08 Sep
Martindale logo
Martindale: The Complete Drug Reference September 2020 Update

This update contains 5 new monographs. Preparations have been updated for 7 countries.

New monographs:

• Cefiderocol is a siderophore cephalosporin approved for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.

• Givosiran, a small interfering RNA, that is used in the treatment of acute hepatic porphyria.

• Lasmiditan is a selective serotonin agonist and can be used to treat acute migraine.

• Luspatercept is a recombinant fusion protein that acts as an erythroid maturation agent. It is used to treat transfusion-dependent anaemia associated with beta-thalassaemia or myelodysplastic syndromes.

• Voxelotor is a haemoglobin oxygen-affinity modulator in the management of sickle-cell disease.

Proprietary Preparations and Manufacturers updated for the following countries and regions:

• Hungary
• Indonesia
• New Zealand
• Russia
• Turkey
• USA†
• UK†
† Countries updated on an ongoing basis

 
09 Jun
Martindale logo
Martindale: The Complete Drug Reference June 2020 Update

This update contains 1 new monograph and 2 existing monographs have been updated. Preparations have been updated for 7 countries.  

New monographs: 

  • Remdesivir is a nucleotide RNA polymerase inhibitor with antiviral activity that is being tried in the treatment of severe COVID-19 (coronavirus disease 2019) infection.

Notable revisions: 

  • Chloroquine is being tried in the treatment of COVID-19 (coronavirus disease 2019) infection.
  • Hydroxychloroquine is being tried in the treatment of COVID-19 (coronavirus disease 2019) infection.

Proprietary Preparations and Manufacturers updated for the following countries and regions: 

  • Chile
  • France
  • Monaco
  • India
  • Ukraine
  • USA
  • UK

† Countries updated on an ongoing basis 

 

10 Mar
Martindale logo
Martindale: The Complete Drug Reference March 2020 Update

This update contains 10 new monographs and 7 existing monographs have been updated. Preparations have been updated for 2 countries.

New monographs:

  • Activin A-neutralising antibodies have been investigated for the treatment of muscle wasting disorders, and may be subject to abuse in sport.
  • 2-Androstenol is reported to be an aromatase inhibitor and may be subject to abuse in sport.
  • 3-Androstenol is reported to be an aromatase inhibitor and may be subject to abuse in sport.
  • 2-Androstenone is reported to be an aromatase inhibitor and may be subject to abuse in sport.
  • 3-Androstenone is reported to be an aromatase inhibitor and may be subject to abuse in sport.
  • 1,2-Dimethylpentylamine may be subject to abuse in sport.
  • 1,4-Dimethylpentylamine may be subject to abuse in sport.
  • Epiandrosterone is reported to be an aromatase inhibitor and may be subject to abuse in sport.
  • 1-Epiandrosterone is reported to be an aromatase inhibitor and may be subject to abuse in sport.
  • Methylclostebol is reported to be an anabolic androgenic steroid and may be subject to abuse in sport.

Notable revisions:

  • Deprodone is a corticosteroid used topically for various skin conditions.
  • Revaprazan is a proton pump inhibitor used for gastritis and peptic ulcer disease.
  • Guanidine hydrochloride is used in the treatment of Eaton-Lambert myasthenic syndrome.

Updated names, synonyms and codes; official standards; official preparations:

  • Drugs in Sport classification updated to reflect WADA Prohibited List 2020

Proprietary Preparations and Manufacturers updated for the following countries and regions:

  • USA†
  • UK†

† Countries updated on an ongoing basis

10 Dec
Martindale logo
Martindale: The Complete Drug Reference December 2019 Update

This update contains 11 new monographs and 13 existing monographs have been updated. Preparations have been updated for 3 countries.  

New monographs: 

  • Alpelisib: is a PI3K inhibitor used for the treatment of HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. 
  • Bremelanotide: is a melanocortin receptor agonist used for the treatment of hypoactive sexual desire disorder in premenopausal women. 
  • Darolutamide: is an anti-androgen used for the treatment of non-metastatic, castration-resistant prostate cancer. 
  • Duvelisib: is a PI3K inhibitor used for the treatment of chronic lymphocytic leukaemia, small lymphocytic lymphoma, and follicular lymphoma. 
  • Erdafitinib: is a tyrosine kinase inhibitor, with activity against the fibroblast growth factor receptor (FGFR), used for the treatment of locally advanced or metastatic urothelial cancer. 
  • Fedratinib: is a Janus kinase JAK2 and FMS-like tyrosine kinase 3 (FLT3) inhibitor used for the treatment of myelofibrosis.
  • Moxetumomab pasudotox: is a CD22-directed cytotoxin, composed of a murine monoclonal antibody fragment fused with a Pseudomonal exotoxin A fragment, used for the treatment of relapsed or refractory hairy-cell leukaemia. 
  • Polatuzumab vedotin: is an antibody-drug conjugate used for the treatment of diffuse large B-cell lymphoma. 
  • Selinexor: is an orally active nuclear export inhibitor used for the treatment of multiple myeloma. 
  • Sotagliflozin: is a dual SGLT1/2 inhibitor used in the management of type 1 diabetes mellitus. 
  • Tenapanor: is a sodium/hydrogen exchanger 3 (NHE3) inhibitor used for the treatment of constipation-predominant irritable bowel syndrome. 

Notable revisions: 

  • Alemtuzumab: serious immune-mediated conditions, stroke, tears in the lining of arteries in the head and neck, and severe neutropenia, including fatalities, have been reported. 
  • Anakinra: can be used for the treatment of Still’s disease. 
  • Asparaginase: calaspargase pegol, a pegylated form of asparaginase, is used for the treatment of acute lymphoblastic leukaemia in children and young adults. 
  • Brivaracetam: can be used in children from 4 years of age for adjunctive therapy and monotherapy of partial onset seizures. 
  • Cannabidiol: can be used for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in patients aged 2 years and older. 
  • Dapagliflozin: necrotising fasciitis of the perineum have been reported in patients taking sodium-glucose co-transporter 2 (SGLT2) inhibitors. 
  • Glucagon: an intranasal formulation can be used for the treatment of severe hypoglycaemia in diabetic patients aged 4 years and older. 
  • Hydrocortisone: muco-adhesive buccal tablets should not be used off-label for adrenal insufficiency due to serious risks. 
  • Lacosamide: can be used as monotherapy or adjunctive therapy in partial seizures, with or without secondary generalisation, in children from 4 years of age. 
  • Midazolam: an intranasal spray can be used for acute treatment of intermittent, stereotypical episodes of increased seizure activity that are distinct from the usual seizure pattern in patients with epilepsy aged 12 years and older. 
  • Mycophenolate: pregnancy abstract updated with advice from the MHRA about its use in female and male patients of reproductive potential. 
  • Ruxolitinib: can be used for the treatment of acute graft-versus-host disease that is steroid refractory in adults and children aged 12 years and older. 
  • Valproate: is considered highly teratogenic and restrictions have been placed on its use during pregnancy. 

Proprietary Preparations and Manufacturers updated for the following countries and regions: 

  • Switzerland 
  • USA
  • UK

† Countries updated on an ongoing basis 

 

10 Sep
Martindale logo
Martindale September 2019 Update

This update contains 10 new monographs and 9 existing monographs have been updated. Preparations have been updated for 4 countries.

New monographs:

  • Benzhydrocodone: an opioid analgesic, is a prodrug of hydrocodone that is given with paracetamol in the short-term treatment of acute pain.
  • Cemiplimab: is a human immunoglobulin G4 monoclonal antibody and immune checkpoint inhibitor that binds to PD-1. It is used in the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.
  • Evocalcet: is a calcimimetic agent used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis.
  • Fexinidazole: is a 5-nitroimidazole derivative with antiprotozoal activity used in the treatment of African trypanosomiasis due to infection with Trypanosoma brucei gambiense (Gambian or West African sleeping sickness). It is also under investigation for the treatment of American trypanosomiasis (Chagas’ disease).
  • Gilteritinib: is a multikinase inhibitor used for the treatment of acute myeloid leukaemia with an FMS-like tyrosine kinase 3 (FLT3) mutation.
  • Pegvaliase: is a recombinant, pegylated form of the enzyme phenylalanine ammonia lyase (PAL). It is used as an adjunct to the dietary restriction of phenylalanine in adults with phenylketonuria.
  • Pemafibrate: a fibric acid derivative, is a lipid regulating drug used in the treatment of hyperlipidaemias.
  • Risankizumab: is a human monoclonal antibody that binds to interleukin-23 and is used in the treatment of plaque psoriasis. It is also under investigation for the treatment of Crohn’s disease and ulcerative colitis.
  • Siponimod: is an immunomodulator used in the treatment of patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
  • Solriamfetol: is a central stimulant that selectively inhibits dopamine and noradrenaline reuptake. It is used in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnoea. Solriamfetol is also under investigation for improving sleep in patients with glioma.

Notable revisions: 

  • Abiraterone acetate: can also be used to treat newly-diagnosed, metastatic hormone-sensitive prostate cancer, in combination with androgen deprivation therapy.
  • Atezolizumab: can now be used to treat metastatic non-small cell lung cancer, advanced or metastatic breast cancer, and extensive-stage small cell lung cancer.
  • Caplacizumab: is a monoclonal antibody that binds to von Willebrand factor that is used in the treatment of acquired thrombotic thrombocytopenic purpura.
  • Ciclosporin eye drops: can be used to treat vernal keratoconjunctivitis in children aged 4 years and over, and in adolescents.
  • Edaravone: is also used in the treatment of amyotrophic lateral sclerosis.
  • Esketamine: is licensed in the UK for use in general anaesthesia, as a supplement to regional and local anaesthesia, and to provide analgesia in emergency care.
  • Fingolimod: is licensed for the treatment of relapsing-remitting MS in children aged 10 years and older. Adverse effects and precautions section also updated.
  • Flupirtine: EMA has recommended the withdrawal of flupirtine from the market in Europe because of continued reports of severe hepatotoxicity
  • Mexiletine: can also be used in adults with myotonia in non-dystrophic myotonic disorders.

Updated names, synonyms and codes; official standards; official preparations:

  • BP 2019
  • USP 42/USNF 37
  • ATC codes

Proprietary Preparations and Manufacturers updated for the following countries and regions:

  • Canada
  • Germany
  • USA
  • UK

† Countries updated on an ongoing basis

11 Jun
Martindale logo
Martindale June 2019 Update

This update contains 38 new monographs and 9 existing monographs have been updated.

Preparations have been updated for 6 countries.

New monographs: 

  • 1,3-Dimethylbutylamine: is a compound related to methylhexaneaminethat may be subject to abuse in sport. 
  • 1-Androsterone: is reported to be an anabolic androgenic steroid that may be subject to abuse in sport.
  • 5α-Androst-2-ene-17-one: is reported to be an anabolic steroid that may be subject to abuse in sport.
  • 5β-Androstane-3α,17-β-diol: is reported to be an anabolic steroid. It may be subject to abuse in sport.
  • Alexamorelin: is reported to be a growth hormone-releasing peptide (GHRP) and may be subject to abuse in sport.
  • α-Pyrrolidinovalerophenone: an analogue of 3,4-methylenedioxypyrovalerone (MDPV), is reported to have stimulant properties and may be subject to abuse in sport.
  • Andarine: is reported to be a selective androgen receptor modulator (SARM). It may be subject to abuse in sport.
  • Androsta-3,5-diene-7,17-dione: is reported to be an aromatase inhibitor. It may be subject to abuse in sport.
  • AOD-9604: is reported to be a modified fragment of the lipolytic domain of human growth hormone. It may be subject to abuse in sport.
  • AsialoEPO: a derivative of erythropoietin (EPO), is reported to be an innate repair receptor agonist. It may be subject to abuse in sport.
  • Brexanolone: is a positive allosteric GABAAreceptor modulator used for the treatment of postpartum depression. 
  • Brodalumab: is an anti-IL-17RA monoclonal antibody, now available for the treatment of moderate to severe plaque psoriasis.
  • Carbamylated EPO: a derivative of erythropoietin (EPO), is reported to be an innate repair receptor agonist. It may be subject to abuse in sport.
  • CJC-1293: is reported to be a growth hormone-releasing hormone (GHRH) analogue and may be subject to abuse in sport.
  • CJC-1295: is reported to be a growth hormone-releasing hormone (GHRH) analogue and may be subject to abuse in sport.
  • CNTO-530: an erythropoietin (EPO) mimetic fusion protein, is reported to be an erythropoietin-receptor agonist. It may be subject to abuse in sport.
  • Dacomitinib: is a tyrosine kinase inhibitor used in the treatment of metastatic non-small cell lung cancer with EGFR mutations.
  • Emapalumab: is an interferon gamma blocking monoclonal antibody used for the treatment of primary haemophagocyticlymphohistiocytosis.
  • EPO-Fc: an erythropoietin (EPO) fusion protein, is reported to be an erythropoietin-receptor agonist. It may be subject to abuse in sport.
  • GHRP-1: is reported to be a growth hormone-releasing peptide (GHRP) and may be subject to abuse in sport.
  • GHRP-3: is reported to be a growth hormone-releasing peptide (GHRP) and may be subject to abuse in sport.
  • GHRP-4: is reported to be a growth hormone-releasing peptide (GHRP) and may be subject to abuse in sport.
  • GHRP-5: is reported to be a growth hormone-releasing peptide (GHRP) and may be subject to abuse in sport.
  • Glasdegib: is an orally active hedgehog pathway inhibitor used in combination with low-dose cytarabine for the treatment of acute myeloid leukaemia.
  • HGH 176-191: is reported to be a human growth hormone (HGH) peptide fragment. It may be subject to abuse in sport.
  • Higenamine: is reported to be a beta2agonist and may be subject to abuse in sport.
  • Inotersen: is a transthyretin-directed antisense oligonucleotide used for the treatment of hereditary transthyretin amyloidosis.
  • K-11706: is reported to be a GATA inhibitor and may be subject to abuse in sport.
  • Ligandrol: is reported to be a selective androgen receptor modulator and may be subject to abuse in sport.
  • Lorlatinib: is a tyrosine kinase inhibitor licensed in the USA for the treatment of ALK-positive metastatic non-small cell lung cancer.
  • Patisiran: is a small interfering ribonucleic acid used in the treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.
  • RAD-140: is reported to be a selective androgen receptor modulator (SARM). It may be subject to abuse in sport.
  • Romosozumab: is a humanised monoclonal antibody that inhibits sclerostin, thereby increasing bone formation and reducing bone resoprtion. It is used in the treatment of osteoporosis.
  • Sarecycline: is a tetracycline derivative used orally in the treatment of moderate to severe acne.
  • SR-9009: is reported to be an AMP-activated protein kinase (AMPK) activator and may be subject to abuse in sport.
  • Tagraxofuspis a CD123-directed cytotoxin used in the treatment of blastic plasmacytoid cell neoplasm.
  • Talazoparibis a PARP inhibitor for the treatment of locally advanced or metastatic breast cancer in patients with germline BRCA gene mutations.
  • TB-500: is reported to be a synthetic fraction of the protein thymosin-β4 that is involved in cellular processes. It may be subject to abuse in sport.

Notable revisions: 

  • Ciprofloxacin: the EMA has placed restrictions on the use of fluoroquinolone and quinolone antibacterialsdue to side effects involving the muscles, tendons or joints and the nervous system. The MHRA and FDA have highlighted the risk of aortic aneurysm and dissection with systemic and inhaled fluoroquinolones. 
  • Dasatinib: can be used in children with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase, and in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia, with chemotherapy.
  • Drugs in sport: World Anti-Doping Agency classifications updated.
  • Doxycycline: can be used for the treatment of acute infections in children aged from 8 years, and in children of any age for the treatment of severe or life threateninginfections such as Rocky Mountain spotted fever.  Doxycycline can also be used in adults for the treatment of Rocky Mountain spotted fever. 
  • Hydrochlorothiazide: increased risk of non-melanoma skin cancer and squamous cell carcinoma of the lip associated with hydrochlorothiazide use.
  • Midostaurin: can be used for the treatment of acute myeloid leukaemia, aggressive systemic mastocytosis(ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL). 
  • Sirolimus: can be used for lymphangioleiomyomatosis. 
  • Sofosbuvir: risk of hypoglycaemia in diabetic patients on direct-acting antiviral therapy.

Proprietary Preparations and Manufacturers updated for the following countries and regions:

  • Israel
  • Italy
  • Japan
  • Poland
  • UK†
  • USA†

† Countries updated on an ongoing basis

View more View all content updates